nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—Hepatocellular injury—Ezetimibe—atherosclerosis	0.0143	0.0342	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Simvastatin—atherosclerosis	0.0137	0.0327	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Pravastatin—atherosclerosis	0.0124	0.0295	CcSEcCtD
Phenylpropanolamine—Urinary retention—Niacin—atherosclerosis	0.00867	0.0207	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Rosuvastatin—atherosclerosis	0.00774	0.0185	CcSEcCtD
Phenylpropanolamine—Flushing—Lovastatin—atherosclerosis	0.00682	0.0163	CcSEcCtD
Phenylpropanolamine—Flushing—Ezetimibe—atherosclerosis	0.00669	0.016	CcSEcCtD
Phenylpropanolamine—Flushing—Simvastatin—atherosclerosis	0.00638	0.0152	CcSEcCtD
Phenylpropanolamine—Confusional state—Rosuvastatin—atherosclerosis	0.00621	0.0148	CcSEcCtD
Phenylpropanolamine—Vision blurred—Lovastatin—atherosclerosis	0.00603	0.0144	CcSEcCtD
Phenylpropanolamine—Tremor—Lovastatin—atherosclerosis	0.00599	0.0143	CcSEcCtD
Phenylpropanolamine—Flushing—Niacin—atherosclerosis	0.00586	0.014	CcSEcCtD
Phenylpropanolamine—Flushing—Pravastatin—atherosclerosis	0.00577	0.0138	CcSEcCtD
Phenylpropanolamine—Vision blurred—Simvastatin—atherosclerosis	0.00564	0.0135	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Niacin—atherosclerosis	0.00564	0.0135	CcSEcCtD
Phenylpropanolamine—Tremor—Simvastatin—atherosclerosis	0.0056	0.0134	CcSEcCtD
Phenylpropanolamine—Insomnia—Rosuvastatin—atherosclerosis	0.00557	0.0133	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Pravastatin—atherosclerosis	0.00555	0.0132	CcSEcCtD
Phenylpropanolamine—Anxiety—Lovastatin—atherosclerosis	0.00543	0.0129	CcSEcCtD
Phenylpropanolamine—Tension—Niacin—atherosclerosis	0.00539	0.0129	CcSEcCtD
Phenylpropanolamine—Nervousness—Niacin—atherosclerosis	0.00533	0.0127	CcSEcCtD
Phenylpropanolamine—Tension—Pravastatin—atherosclerosis	0.00531	0.0127	CcSEcCtD
Phenylpropanolamine—Constipation—Rosuvastatin—atherosclerosis	0.00527	0.0126	CcSEcCtD
Phenylpropanolamine—Confusional state—Lovastatin—atherosclerosis	0.00526	0.0126	CcSEcCtD
Phenylpropanolamine—Nervousness—Pravastatin—atherosclerosis	0.00525	0.0125	CcSEcCtD
Phenylpropanolamine—Vision blurred—Niacin—atherosclerosis	0.00518	0.0124	CcSEcCtD
Phenylpropanolamine—Confusional state—Ezetimibe—atherosclerosis	0.00516	0.0123	CcSEcCtD
Phenylpropanolamine—Vision blurred—Pravastatin—atherosclerosis	0.0051	0.0122	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00507	0.0121	CcSEcCtD
Phenylpropanolamine—Anxiety—Simvastatin—atherosclerosis	0.00507	0.0121	CcSEcCtD
Phenylpropanolamine—Tremor—Pravastatin—atherosclerosis	0.00507	0.0121	CcSEcCtD
Phenylpropanolamine—Confusional state—Simvastatin—atherosclerosis	0.00492	0.0117	CcSEcCtD
Phenylpropanolamine—Insomnia—Lovastatin—atherosclerosis	0.00472	0.0113	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Lovastatin—atherosclerosis	0.00465	0.0111	CcSEcCtD
Phenylpropanolamine—Insomnia—Ezetimibe—atherosclerosis	0.00463	0.011	CcSEcCtD
Phenylpropanolamine—Anxiety—Pravastatin—atherosclerosis	0.00459	0.0109	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Ezetimibe—atherosclerosis	0.00456	0.0109	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00454	0.0108	CcSEcCtD
Phenylpropanolamine—Constipation—Lovastatin—atherosclerosis	0.00446	0.0107	CcSEcCtD
Phenylpropanolamine—Confusional state—Pravastatin—atherosclerosis	0.00445	0.0106	CcSEcCtD
Phenylpropanolamine—Insomnia—Simvastatin—atherosclerosis	0.00442	0.0105	CcSEcCtD
Phenylpropanolamine—Constipation—Ezetimibe—atherosclerosis	0.00438	0.0104	CcSEcCtD
Phenylpropanolamine—Tachycardia—Niacin—atherosclerosis	0.00437	0.0104	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Simvastatin—atherosclerosis	0.00435	0.0104	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Lovastatin—atherosclerosis	0.0043	0.0103	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Ezetimibe—atherosclerosis	0.00422	0.0101	CcSEcCtD
Phenylpropanolamine—Hypotension—Niacin—atherosclerosis	0.00419	0.01	CcSEcCtD
Phenylpropanolamine—Constipation—Simvastatin—atherosclerosis	0.00417	0.00996	CcSEcCtD
Phenylpropanolamine—Dizziness—Rosuvastatin—atherosclerosis	0.00407	0.00972	CcSEcCtD
Phenylpropanolamine—Insomnia—Niacin—atherosclerosis	0.00405	0.00968	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Simvastatin—atherosclerosis	0.00402	0.0096	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Niacin—atherosclerosis	0.004	0.00954	CcSEcCtD
Phenylpropanolamine—Insomnia—Pravastatin—atherosclerosis	0.00399	0.00953	CcSEcCtD
Phenylpropanolamine—Somnolence—Niacin—atherosclerosis	0.00398	0.00951	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Pravastatin—atherosclerosis	0.00393	0.00939	CcSEcCtD
Phenylpropanolamine—Rash—Rosuvastatin—atherosclerosis	0.00388	0.00927	CcSEcCtD
Phenylpropanolamine—Dermatitis—Rosuvastatin—atherosclerosis	0.00388	0.00926	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Lovastatin—atherosclerosis	0.00385	0.00918	CcSEcCtD
Phenylpropanolamine—Constipation—Pravastatin—atherosclerosis	0.00377	0.00901	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Ezetimibe—atherosclerosis	0.00377	0.009	CcSEcCtD
Phenylpropanolamine—Nausea—Rosuvastatin—atherosclerosis	0.00366	0.00873	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Pravastatin—atherosclerosis	0.00364	0.00868	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Simvastatin—atherosclerosis	0.0036	0.00858	CcSEcCtD
Phenylpropanolamine—Dizziness—Lovastatin—atherosclerosis	0.00345	0.00824	CcSEcCtD
Phenylpropanolamine—Dizziness—Ezetimibe—atherosclerosis	0.00339	0.00808	CcSEcCtD
Phenylpropanolamine—Vomiting—Lovastatin—atherosclerosis	0.00332	0.00792	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Niacin—atherosclerosis	0.0033	0.00788	CcSEcCtD
Phenylpropanolamine—Rash—Lovastatin—atherosclerosis	0.00329	0.00785	CcSEcCtD
Phenylpropanolamine—Dermatitis—Lovastatin—atherosclerosis	0.00329	0.00785	CcSEcCtD
Phenylpropanolamine—Vomiting—Ezetimibe—atherosclerosis	0.00325	0.00777	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Pravastatin—atherosclerosis	0.00325	0.00776	CcSEcCtD
Phenylpropanolamine—Dizziness—Simvastatin—atherosclerosis	0.00323	0.0077	CcSEcCtD
Phenylpropanolamine—Rash—Ezetimibe—atherosclerosis	0.00323	0.0077	CcSEcCtD
Phenylpropanolamine—Dermatitis—Ezetimibe—atherosclerosis	0.00322	0.0077	CcSEcCtD
Phenylpropanolamine—Vomiting—Simvastatin—atherosclerosis	0.0031	0.00741	CcSEcCtD
Phenylpropanolamine—Nausea—Lovastatin—atherosclerosis	0.0031	0.0074	CcSEcCtD
Phenylpropanolamine—Rash—Simvastatin—atherosclerosis	0.00308	0.00735	CcSEcCtD
Phenylpropanolamine—Dermatitis—Simvastatin—atherosclerosis	0.00308	0.00734	CcSEcCtD
Phenylpropanolamine—Nausea—Ezetimibe—atherosclerosis	0.00304	0.00726	CcSEcCtD
Phenylpropanolamine—Dizziness—Niacin—atherosclerosis	0.00296	0.00707	CcSEcCtD
Phenylpropanolamine—Dizziness—Pravastatin—atherosclerosis	0.00292	0.00697	CcSEcCtD
Phenylpropanolamine—Nausea—Simvastatin—atherosclerosis	0.0029	0.00692	CcSEcCtD
Phenylpropanolamine—Vomiting—Niacin—atherosclerosis	0.00285	0.0068	CcSEcCtD
Phenylpropanolamine—Rash—Niacin—atherosclerosis	0.00283	0.00675	CcSEcCtD
Phenylpropanolamine—Dermatitis—Niacin—atherosclerosis	0.00282	0.00674	CcSEcCtD
Phenylpropanolamine—Vomiting—Pravastatin—atherosclerosis	0.00281	0.0067	CcSEcCtD
Phenylpropanolamine—Rash—Pravastatin—atherosclerosis	0.00278	0.00664	CcSEcCtD
Phenylpropanolamine—Dermatitis—Pravastatin—atherosclerosis	0.00278	0.00664	CcSEcCtD
Phenylpropanolamine—Nausea—Niacin—atherosclerosis	0.00266	0.00635	CcSEcCtD
Phenylpropanolamine—Nausea—Pravastatin—atherosclerosis	0.00262	0.00626	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—F2—atherosclerosis	9.73e-05	0.000167	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VEGFA—atherosclerosis	9.7e-05	0.000167	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL5—atherosclerosis	9.68e-05	0.000167	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—LPL—atherosclerosis	9.67e-05	0.000166	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—BGN—atherosclerosis	9.59e-05	0.000165	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KNG1—atherosclerosis	9.57e-05	0.000165	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	9.52e-05	0.000164	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AGTR1—atherosclerosis	9.52e-05	0.000164	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—HMOX1—atherosclerosis	9.51e-05	0.000164	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PPARG—atherosclerosis	9.5e-05	0.000164	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOA5—atherosclerosis	9.49e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—LPL—atherosclerosis	9.46e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PDGFB—atherosclerosis	9.43e-05	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PRKCG—atherosclerosis	9.41e-05	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CCL2—atherosclerosis	9.34e-05	0.000161	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—INS—atherosclerosis	9.32e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CG—atherosclerosis	9.31e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PLG—atherosclerosis	9.27e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	9.22e-05	0.000159	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AGT—atherosclerosis	9.21e-05	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PRKCG—atherosclerosis	9.2e-05	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—MAPK3—atherosclerosis	9.18e-05	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SPP1—atherosclerosis	9.16e-05	0.000158	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	9.14e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CXCL8—atherosclerosis	9.12e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOB—atherosclerosis	9.11e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	9.04e-05	0.000156	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—LEP—atherosclerosis	9.02e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOE—atherosclerosis	9.02e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SPP1—atherosclerosis	8.96e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	8.95e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CAV1—atherosclerosis	8.94e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	8.93e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CXCL8—atherosclerosis	8.92e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOA1—atherosclerosis	8.92e-05	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TGFB1—atherosclerosis	8.91e-05	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KNG1—atherosclerosis	8.89e-05	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTM1—atherosclerosis	8.86e-05	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AGTR1—atherosclerosis	8.84e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALOX5—atherosclerosis	8.83e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SOCS3—atherosclerosis	8.78e-05	0.000151	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—LPL—atherosclerosis	8.7e-05	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCL2—atherosclerosis	8.67e-05	0.000149	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PLG—atherosclerosis	8.62e-05	0.000148	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ESR1—atherosclerosis	8.61e-05	0.000148	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ALB—atherosclerosis	8.55e-05	0.000147	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—F2—atherosclerosis	8.51e-05	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GPX1—atherosclerosis	8.49e-05	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP3—atherosclerosis	8.48e-05	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PDGFB—atherosclerosis	8.48e-05	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF2—atherosclerosis	8.44e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PDGFB—atherosclerosis	8.29e-05	0.000143	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AGT—atherosclerosis	8.28e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CD36—atherosclerosis	8.26e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOB—atherosclerosis	8.2e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—NOS3—atherosclerosis	8.17e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SOCS3—atherosclerosis	8.16e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	8.16e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CG—atherosclerosis	8.14e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CXCL8—atherosclerosis	8.13e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—LEP—atherosclerosis	8.11e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—atherosclerosis	8.11e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AGT—atherosclerosis	8.1e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EDN1—atherosclerosis	8.07e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CAV1—atherosclerosis	8.03e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOA1—atherosclerosis	8.02e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL5—atherosclerosis	8e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—atherosclerosis	7.93e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—LEP—atherosclerosis	7.93e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NAMPT—atherosclerosis	7.92e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	7.88e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	7.87e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LIPC—atherosclerosis	7.87e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CAV1—atherosclerosis	7.86e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	7.85e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOA1—atherosclerosis	7.84e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MTHFR—atherosclerosis	7.83e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LPL—atherosclerosis	7.83e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOC3—atherosclerosis	7.82e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—MAPK3—atherosclerosis	7.8e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LDLR—atherosclerosis	7.77e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ESR1—atherosclerosis	7.74e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—INS—atherosclerosis	7.71e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARA—atherosclerosis	7.68e-05	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—F2—atherosclerosis	7.65e-05	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOB—atherosclerosis	7.62e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRKCG—atherosclerosis	7.61e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CETP—atherosclerosis	7.59e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCL2—atherosclerosis	7.58e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ESR1—atherosclerosis	7.57e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	7.55e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	7.5e-05	0.000129	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—F2—atherosclerosis	7.48e-05	0.000129	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—atherosclerosis	7.48e-05	0.000129	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1—atherosclerosis	7.45e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AGT—atherosclerosis	7.44e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	7.44e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	7.41e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	7.38e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CG—atherosclerosis	7.32e-05	0.000126	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—atherosclerosis	7.29e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LPL—atherosclerosis	7.27e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SCARB1—atherosclerosis	7.27e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CAV1—atherosclerosis	7.22e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOA1—atherosclerosis	7.21e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CG—atherosclerosis	7.16e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SERPINE1—atherosclerosis	7.08e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	7.08e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	7.07e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—MAPK3—atherosclerosis	7.01e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—INS—atherosclerosis	6.93e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	6.89e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMGCR—atherosclerosis	6.86e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	6.86e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	6.86e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—MAPK3—atherosclerosis	6.86e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCL2—atherosclerosis	6.82e-05	0.000117	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—INS—atherosclerosis	6.78e-05	0.000117	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NOS3—atherosclerosis	6.76e-05	0.000116	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1—atherosclerosis	6.7e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AGT—atherosclerosis	6.7e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL2—atherosclerosis	6.67e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CG—atherosclerosis	6.58e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LEP—atherosclerosis	6.56e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—atherosclerosis	6.56e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1—atherosclerosis	6.55e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	6.5e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	6.49e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	6.37e-05	0.00011	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SERPINE1—atherosclerosis	6.36e-05	0.00011	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARG—atherosclerosis	6.35e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	6.26e-05	0.000108	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—INS—atherosclerosis	6.23e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SERPINE1—atherosclerosis	6.22e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AGT—atherosclerosis	6.22e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—atherosclerosis	6.19e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.19e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—F2—atherosclerosis	6.19e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCA1—atherosclerosis	6.12e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—atherosclerosis	6.1e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LEP—atherosclerosis	6.1e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOS3—atherosclerosis	6.07e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	6.04e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	6.03e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCL8—atherosclerosis	5.99e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOS3—atherosclerosis	5.94e-05	0.000102	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	5.92e-05	0.000102	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	5.82e-05	0.0001	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—atherosclerosis	5.79e-05	9.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—F2—atherosclerosis	5.75e-05	9.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—atherosclerosis	5.71e-05	9.83e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—atherosclerosis	5.7e-05	9.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	5.67e-05	9.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—INS—atherosclerosis	5.6e-05	9.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	5.51e-05	9.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	5.5e-05	9.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NOS3—atherosclerosis	5.46e-05	9.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	5.42e-05	9.33e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—atherosclerosis	5.42e-05	9.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	5.39e-05	9.27e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NFKB1—atherosclerosis	5.36e-05	9.23e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK8—atherosclerosis	5.27e-05	9.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	5.27e-05	9.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	5.27e-05	9.07e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—atherosclerosis	5.26e-05	9.05e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMOX1—atherosclerosis	5.25e-05	9.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—INS—atherosclerosis	5.21e-05	8.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	5.21e-05	8.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	5.15e-05	8.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—atherosclerosis	5.12e-05	8.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	5.12e-05	8.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	5.09e-05	8.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	5.04e-05	8.67e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOB—atherosclerosis	5.03e-05	8.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—atherosclerosis	5.01e-05	8.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—atherosclerosis	5e-05	8.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	4.92e-05	8.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.89e-05	8.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—atherosclerosis	4.87e-05	8.39e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—atherosclerosis	4.87e-05	8.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	4.82e-05	8.3e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—atherosclerosis	4.82e-05	8.3e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LPL—atherosclerosis	4.8e-05	8.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	4.78e-05	8.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—atherosclerosis	4.77e-05	8.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	4.74e-05	8.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	4.73e-05	8.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	4.72e-05	8.12e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPX1—atherosclerosis	4.68e-05	8.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	4.64e-05	7.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	4.62e-05	7.96e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK3—atherosclerosis	4.61e-05	7.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	4.57e-05	7.86e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CD36—atherosclerosis	4.56e-05	7.85e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—atherosclerosis	4.47e-05	7.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	4.38e-05	7.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	4.36e-05	7.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—atherosclerosis	4.33e-05	7.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—atherosclerosis	4.32e-05	7.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	4.28e-05	7.37e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARA—atherosclerosis	4.24e-05	7.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—atherosclerosis	4.24e-05	7.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	4.21e-05	7.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	4.15e-05	7.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	4.14e-05	7.13e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AGT—atherosclerosis	4.11e-05	7.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	4.05e-05	6.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	4.05e-05	6.97e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—atherosclerosis	4.02e-05	6.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	4.02e-05	6.91e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAV1—atherosclerosis	3.99e-05	6.86e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOA1—atherosclerosis	3.98e-05	6.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	3.94e-05	6.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	3.93e-05	6.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	3.91e-05	6.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	3.9e-05	6.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	3.85e-05	6.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	3.84e-05	6.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	3.82e-05	6.58e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—atherosclerosis	3.76e-05	6.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	3.66e-05	6.31e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.63e-05	6.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	3.63e-05	6.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	3.56e-05	6.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	3.55e-05	6.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	3.54e-05	6.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	3.51e-05	6.03e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARG—atherosclerosis	3.51e-05	6.03e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—INS—atherosclerosis	3.44e-05	5.92e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—atherosclerosis	3.37e-05	5.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	3.35e-05	5.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	3.29e-05	5.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	3.26e-05	5.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	3.25e-05	5.59e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—atherosclerosis	3.15e-05	5.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	3.11e-05	5.36e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—atherosclerosis	3.11e-05	5.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—atherosclerosis	3.03e-05	5.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	3.02e-05	5.2e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NOS3—atherosclerosis	3.01e-05	5.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—atherosclerosis	2.96e-05	5.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—atherosclerosis	2.79e-05	4.81e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.76e-05	4.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—atherosclerosis	2.73e-05	4.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—atherosclerosis	2.51e-05	4.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	2.45e-05	4.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	2.28e-05	3.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	2.26e-05	3.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	2.1e-05	3.61e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—atherosclerosis	1.39e-05	2.39e-05	CbGpPWpGaD
